Cardiac troponins: mechanisms of release and new options for diagnosis and prognosis of cardiovascular disease (literature review)

The modern high-sensitivity methods for cardiac troponin measurement make it possible to determine their concentration in the majority of individuals in the population, which makes it possible to detect subclinical myocardial damage. Current data on the molecular mechanisms of troponin release explain the associations between troponin levels and the development of adverse cardiovascular events in both asymptomatic individuals and patients with cardiovascular disease.

Aim: To summarize the available data on laboratory methods for determining cardiac troponins and the mechanisms of their release, as well as the opportunities to use them for the diagnosis and prognosis of cardiovascular diseases in various clinical situations. Existing problems in the field of methodology for determining these biomarkers and possible ways to solve them are discussed. This article also addresses the issues of restratification of cardiovascular risk in the general population using cardiac troponins, as well as the use of these markers in groups of patients with a history of cardiovascular disease (patients with coronary heart disease, stroke, chronic heart failure). The use of troponins in these patients may help to individualize primary and secondary prevention. The review demonstrates that cardiac troponins are currently one of the most promising biomarkers of cardiovascular diseases, since they have high reproducibility and specificity, and their determination can influence the management of patients in a wide range of clinical situations.

1. Boytsov S.A., Shalnova S.A., Deev A.D. Cardiovascular mortality in the Russian Federation and possible mechanisms of its changes. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(8):98– 103. (In Russ.). https://doi.org/10.17116/jnevro201811808198

2. Kontsevaya A.V., Myrzamatova A.О., Drapkina O.M. Biomarkers in predicting cardiovascular risk: new prospects of troponin I. Cardiovascular Therapy and Prevention. 2020;19(3):2584. (In Russ.). https://doi.org/10.15829/1728-8800-2020-2584

3. Lazar D.R., Lazar F.L., Homorodean C., Cainap C., Focsan M., Cainap S. et al. High-sensitivity troponin: A review on characteristics, assessment, and clinical implications. Dis. Markers. 2022;2022:9713326. https://doi.org/10.1155/2022/9713326

4. Creso J.G., Campbell S.G. Potential impacts of the cardiac troponin I mobile domain on myofilament activation and relaxation. J. Mol. Cell. Cardiol. 2021;155:50–57. https://doi.org/10.1016/j.yjmcc.2021.02.012

5. Gokhan I., Dong W., Grubman D., Mezue K., Yang D., Wang Y. et al. Clinical biochemistry of serum troponin. Diagnostics (Basel). 2024;14(4):378. https://doi.org/10.3390/diagnostics14040378

6. Clerico A., Zaninotto M., Padoan A., Masotti S., Musetti V., Prontera C. et al. Evaluation of analytical performance of immunoassay methods for cTnI and cTnT: From theory to practice. Adv. Clin. Chem. 2019;93:239– 262. https://doi.org/10.1016/bs.acc.2019.07.005

7. Ragusa R., Masotti S., Musetti V., Rocchiccioli S., Prontera C., Perrone M. et al. Cardiac troponins: Mechanisms of release and role in healthy and diseased subjects. Biofactors. 2023;49(2):351–364. https://doi.org/10.1002/biof.1925

8. Chaulin A.M. The metabolic pathway of cardiac troponins release: Mechanisms and diagnostic role. Cardiol. Res. 2022;13(4):190–205. https://doi.org/10.14740/cr1351

9. Hammarsten O., Mair J., Möckel M., Lindahl B., Jaffe A.S. Possible mechanisms behind cardiac troponin elevations. Biomarkers. 2018;23(8):725–734. https://doi.org/10.1080/1354750x.2018.1490969

10. Lázár E., Sadek H.A., Bergmann O. Cardiomyocyte renewal in the human heart: insights from the fall-out. Eur. Heart J. 2017;38(30):2333– 2342. https://doi.org/10.1093/eurheartj/ehx343

11. Hessel M.H., Atsma D.E., van der Valk E.J., Bax W.H., Schalij M.J., van der Laarse A. Release of cardiac troponin I from viable cardiomyocytes is mediated by integrin stimulation. Pflugers Arch. 2008;455(6):979–986. https://doi.org/10.1007/s00424-007-0354-8

12. Martin-Garrido A., Biesiadecki B.J., Salhi H.E., Shaifta Y., Dos Remedios C.G., Ayaz-Guner S. et al. Monophosphorylation of cardiac troponin-I at Ser-23/24 is sufficient to regulate cardiac myofibrillar Ca2+ sensitivity and calpain-induced proteolysis. J. Biol. Chem. 2018;293(22):8588– 8599. https://doi.org/10.1074/jbc.RA117.001292

13. Wu F., Minteer S.D. Tricarboxylic acid metabolon. Methods Enzymol. 2019;617:29–43. https://doi.org/10.1016/bs.mie.2018.12.002

14. Wens S.C., Schaaf G.J., Michels M., Kruijshaar M.E., van Gestel T.J., In 't Groen S. et al. Elevated plasma cardiac troponin T levels caused by skeletal muscle damage in Pompe disease. Circ. Cardiovasc. Genet. 2016;9(1):6–13. https://doi.org/10.1161/circgenetics.115.001322

15. Schmid J., Liesinger L., Birner-Gruenberger R., Stojakovic T., Scharnagl H., Dieplinger B. et al. Elevated cardiac troponin T in patients with skeletal myopathies. J. Am. Coll. Cardiol. 2018;71(14):1540–1549. https://doi.org/10.1016/j.jacc.2018.01.070

16. Fridén V., Starnberg K., Muslimovic A., Ricksten S.E., Bjurman C., Forsgard N. et al. Clearance of cardiac troponin T with and without kidney function. Clin. Biochem. 2017;50(9):468–474. https://doi.org/10.1016/j.clinbiochem.2017.02.007

17. Chaulin A.M., Abashina O.E., Duplyakov D.V. High-sensitivity cardiac troponins: detection and central analytical characteristics. Cardiovascular Therapy and Prevention. 2021;20(2):2590. (In Russ.). https://doi.org/10.15829/1728-8800-2021-2590

18. Collinson P. High sensitivity troponin, analytical advantages, clinical ben efits and clinical challenges – An update. Clin. Biochem. 2021;91:1–8. https://doi.org/10.1016/j.clinbiochem.2021.02.001

19. Farmakis D., Richter D., Chronopoulou G., Goumas G., Kountouras D., Mastorakou A. et al. High-sensitivity cardiac troponin I for cardiovascular risk stratification in apparently healthy individuals. Hellenic. J. Cardiol. 2024;75:74–81. https://doi.org/10.1016/j.hjc.2023.09.011

20. Maayah M., Grubman S., Allen S., Ye Z., Park D.Y., Vemmou E. et al. Clinical interpretation of serum troponin in the era of high-sensitivity testing. Diagnostics (Basel). 2024;14(5):503. https://doi.org/10.3390/diagnostics14050503

21. Apple F.S., Jaffe A.S., Collinson P., Mockel M., Ordonez-Llanos J., Lindahl B. et al. IFCC educational materials on selected analytical and clinical applications of high sensitivity cardiac troponin assays. Clin. Biochem. 2015;48(4–5):201–203. https://doi.org/10.1016/j.clinbiochem.2014.08.021

22. Jakubiak G.K. Cardiac troponin serum concentration measurement is useful not only in the diagnosis of acute cardiovascular events. J. Pers. Med. 2024;14(3):230. https://doi.org/10.3390/jpm14030230

23. Blankenberg S., Salomaa V., Makarova N., Ojeda F., Wild P., Lackner K.J. et al. Troponin I and cardiovascular risk prediction in the general population: The BiomarCaRE consortium. Eur. Heart J. 2016;37:2428– 2437. https://doi.org/10.1093/eurheartj/ehw172

24. Drapkina O.M., Shalnova S.A., Kontsevaya A.V., Kutsenko V.A., Kapustina A.V., Balanova Yu.A. et al. Prognostic significance of troponin I in assessing cardiovascular risk in the Russian population. Data from ESSERF1 and ESSE-RF2 multicenter studies. Cardiovascular Therapy and Prevention. 2023;22(5):3548. (In Russ.). https://doi.org/10.15829/1728-8800-2023-3548

25. Jia X., Sun W., Hoogeveen R.C., Nambi V., Matsushita K., Folsom A.R. et al. High-sensitivity troponin I and incident coronary events, stroke, heart failure hospitalization, and mortality in the ARIC study. Circulation. 2019;139(23):2642–2653. https://doi.org/10.1161/circulationaha.118.038772

26. Thorsteinsdottir I., Aspelund T., Gudmundsson E., Eiriksdottir G., Harris T.B., Launer L.J. et al. High-sensitivity cardiac troponin I is a strong predictor of cardiovascular events and mortality in the AGES-Reykjavik community-based cohort of older individuals. Clin. Chem. 2016;62:623– 630. https://doi.org/10.1373/clinchem.2015.250811

27. Hageman S.H.J., Petitjaen C., Pennells L., Kaptoge S., Pajouheshnia R., Tillmann T. et al. Improving 10-year cardiovascular risk prediction in apparently healthy people: flexible addition of risk modifiers on top of SCORE2. Eur. J. Prev. Cardiol. 2023;30(15):1705–1714. Erratum in: Eur. J. Prev. Cardiol. 2024;31(13):e103. https://doi.org/10.1093/eurjpc/zwad187

28. Kimenai D.M., Anand A., de Bakker M., Shipley M., Fujisawa T., Lyngbakken M.N. et al. Trajectories of cardiac troponin in the decades before cardiovascular death: a longitudinal cohort study. BMC Med. 2023;21(1):216. https://doi.org/10.1186/s12916-023-02921-8

29. Neumann J.T., Twerenbold R., Weimann J., Ballantyne C.M., Benjamin E.J., Costanzo S. et al. Prognostic value of cardiovascular biomarkers in the population. JAMA. 2024;331(22):1898–1909. https://doi.org/10.1001/jama.2024.5596

30. Samorodskaya I.V., Bubnova M.G., Akulova O.A., Drapkina O. M. Male and female mortality rates due to acute types of coronary artery disease in five-year age groups in the Russian Federation: what do the numbers mean? Cardiovascular Therapy and Prevention. 2022;21(12):3460. https://doi.org/10.15829/1728-8800-2022-3460

31. Nedkoff L., Greenland M., Hyun K., Htun J.P., Redfern J., Stiles S. et al. Sex- and age-specific differences in risk profiles and early outcomes in adults with acute coronary syndromes. Heart Lung Circ. 2024;33(3):332– 341. https://doi.org/10.1016/j.hlc.2023.11.016

32. Adamson P.D., Hunter A., Madsen D.M., Shah A.S.V., McAllister D.A., Pawade T.A. et al. High-sensitivity cardiac troponin I and the diagnosis of coronary artery disease in patients with suspected angina pectoris. Circ. Cardiovasc. Qual. Outcomes. 2018;11(2):e004227. https://doi.org/10.1161/CIRCOUTCOMES.117.004227

33. Tveit S.H., Myhre P.L., Hanssen T.A., Forsdahl S.H., Iqbal A., Omland T. et al. Cardiac troponin I and T for ruling out coronary artery disease in suspected chronic coronary syndrome. Sci. Rep. 2022;12(1):945. https://doi.org/10.1038/s41598-022-04850-7

34. Bay B., Goßling A., Blaum C.M., Kroeger F., Koppe L., Lorenz T. et al. Association of high-sensitivity troponin T and I blood concentrations with all-cause mortality and cardiovascular outcome in stable patients-results from the INTERCATH Cohort. J. Am. Heart Assoc. 2022;11(17):e024516. https://doi.org/10.1161/jaha.121.024516

35. Biener M., Giannitsis E., Kuhner M., Zelniker T., Mueller-Hennessen M., Vafaie M. et al. Risk prediction in stable cardiovascular disease using a high-sensitivity cardiac troponin T single biomarker strategy compared to the ESC-SCORE. Open Heart. 2018;5(1):e000710. https://doi.org/10.1136/openhrt-2017-000710

36. Wereski R., Adamson P., Shek Daud N.S., McDermott M., Taggart C., Bularga A. et al. High-sensitivity cardiac troponin for risk assessment in patients with chronic coronary artery disease. J. Am. Coll. Cardiol. 2023;82(6):473–485. https://doi.org/10.1016/j.jacc.2023.05.046

37. Beatty A.L., Ku I.A., Bibbins-Domingo K., Christenson R.H., DeFilippi C.R., Ganz P. et al. Traditional risk factors versus biomarkers for prediction of secondary events in patients with stable coronary heart disease: From the heart and soul study. J. Am. Heart Assoc. 2015;4(7):e001646. https://doi.org/10.1161/jaha.114.001646

38. Jia X., Al Rifai M., Ndumele C.E., Virani S.S., de Lemos J.A., Lee E. et al. Reclassification of pre-heart failure stages using cardiac biomarkers: The ARIC Study. JACC Heart Fail. 2023;11(4):440–450. https://doi.org/10.1016/j.jchf.2022.12.005

39. Tian P., Zhao X., Huang L., Feng J., Zhao L., Liang L. et al. Prognostic value of high-sensitivity cardiac troponin I in patients with non-ischaemic heart failure: insights from China. ESC Heart Fail. 2022;9(5):3345–3357. https://doi.org/10.1002/ehf2.14065

40. Pocock S.J., Ferreira J.P., Packer M., Zannad F., Filippatos G., Kondo T. et al. Biomarker-driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR-Preserved trial. Eur. J. Heart Fail. 2022;24(10):1869–1878. https://doi.org/10.1002/ejhf.2607

41. Ledwoch J., Kraxenberger J., Krauth A., Schneider A., Leidgschwendner K., Schneider V. et al. Prognostic impact of high-sensitive troponin on 30-day mortality in patients with acute heart failure and different classes of left ventricular ejection fraction. Heart Vessels. 2022;37(7):1195– 1202. https://doi.org/10.1007/s00380-022-02026-x

42. D'Amato A., Severino P., Prosperi S., Mariani M.V., Germanò R., De Prisco A. et al. The role of high-sensitivity troponin T regarding prognosis and cardiovascular outcome across heart failure spectrum. J. Clin. Med. 2024;13(12):3533. https://doi.org/10.3390/jcm13123533

43. Dous G.V., Grigos A.C., Grodman R. Elevated troponin in patients with acute stroke – Is it a true heart attack? Egypt. Heart J. 2017;69(3):165– 170. https://doi.org/10.1016/j.ehj.2017.01.005

44. Samuels M.A. The brain-heart connection. Circulation. 2007;116(1):77– 84. https://doi.org/10.1161/circulationaha.106.678995

45. Zhang Y., Ouyang M., Qiu J., Cao X., Xu B., Sui Y. Prognostic value of serum cardiac troponin in acute ischemic stroke: An updated systematic review and meta-analysis. J. Stroke Cerebrovasc. Dis. 2022;31(6):106444. https://doi.org/10.1016/j.jstrokecerebrovasdis.2022.106444

46. Huang J., Liu M., Su E., Yu P., Jiang H., Zhao J. et al. Elevated circulating high-sensitivity cardiac troponin T and cardiac remodeling in obesity. BMC Cardiovasc. Disord. 2021;21(1):620. https://doi.org/10.1186/s12872-021-02445-0

47. Watanabe H., Hoshide S., Kanegae H., Kario K. Prognosis of a malignant phenotype of obesity defined by a cardiac biomarker in hypertension: the Japan Morning Surge-Home Blood Pressure study. Hypertens. Res. 2024;47(2):487–495. https://doi.org/10.1038/s41440-023-01468-8

48. Bagriy A.E., Suprun E.V., Mikhaylichenko E.S., Golodnikov I.A. Heart failure and type 2 diabetes: current state of the problem. Russian Journal of Cardiology. 2020;25(4):3858. (In Russ.). https://doi.org/10.15829/1560-4071-2020-3858

49. Hamo C.E., Echouffo-Tcheugui J.B., Zhang S., Florido R., Pankow J.S., Michos E.D. et al. Diabetes duration and subclinical myocardial injury: The Atherosclerosis Risk in Communities Study (ARIC). Clin. Chem. 2022;68(10):1272–1280. https://doi.org/10.1093/clinchem/hvac117

50. Vrsalovic M., Vrsalovic Presecki A., Aboyans V. Cardiac troponins predict mortality and cardiovascular outcomes in patients with peripheral artery disease: A systematic review and meta-analysis of adjusted observational studies. Clin. Cardiol. 2022;45(2):198–204. https://doi.org/10.1002/clc.23776